Keynote Presentation: Outsmarting the Escape Artist Resistance in CAR-T Cell Therapy for... @Labroots
Keynote Presentation: Outsmarting the Escape Artist Resistance in CAR-T Cell Therapy for...  @Labroots
Uploaded December 2025 | Updated November 2026, 6 hours ago
Presented By: Marco Ruella, MD



Speaker Biography: Dr. Marco Ruella is a physician-scientist and assistant professor at the University of Pennsylvania. He treats patients with blood cancers and focuses on using immunotherapy, where the body’s own immune system is harnessed to fight cancer. His research looks at why some cancers return after CAR T-cell therapy and aims to design new treatments to prevent this. Dr. Ruella earned his medical degree in Italy and completed advanced training in the U.S. He has received many awards for his work, including from the American Society for Clinical Investigation and the Leukemia & Lymphoma Society. Dr. Ruella has published widely, holds multiple patents, and advises companies in cancer immunotherapy. He also founded viTToria Biotherapeutics to help bring new treatments to patients.



Webinar: Keynote Presentation: Outsmarting the Escape Artist: Resistance in CAR T-Cell Therapy for Hematologic Cancers w/ Live Q&A



Webinar Abstract: Despite remarkable success in relapsed or refractory B-cell malignancies, CAR T-cell therapy faces significant challenges: primary resistance, relapse, and treatment-related toxicities. This talk reviews clinical outcomes of FDA-approved CAR T products and highlights emerging mechanisms of resistance—including tumor-intrinsic factors such as CD58 loss, host microenvironmental barriers, and T-cell exhaustion. Dr. Ruella will present pre-clinical and clinical data on novel strategies to overcome these obstacles: engineering PD-1:intracellular-CD2 switch receptors to restore CD2–CD58 co-stimulation; leveraging metabolic modulation with the ketogenic diet and β-hydroxybutyrate to enhance CAR T oxidative phosphorylation and persistence; and applying CD5-knockout CAR T cells to treat T-cell lymphomas while preserving immune competence. Attendees will gain a translational perspective on next-generation CAR T design and how these innovations may broaden indications, improve durability of response, and reduce toxicity in hematologic cancers.

Learning Objectives:

1. Analyze clinical and biologic mechanisms that drive primary and acquired resistance to CAR T-cell therapy in B-cell malignancies.

2. Analyze clinical and biologic mechanisms that drive primary and acquired resistance to CAR T-cell therapy in B-cell malignancies.

3. Discuss translational approaches for expanding CAR T therapy to T-cell lymphomas and autoimmune diseases while mitigating toxicity.



Earn PACE Credits: 1. Make sure you’re a registered member of Labroots (labroots.com/virtual-event/cell-gene-therapy-2025) 2. Watch the webinar on YouTube or on the Labroots Website (labroots.com/virtual-event/cell-gene-therapy-2025/agenda) 3. Click Here to get your PACE credits (Expiration date – 10/15/2026): (labroots.com/virtual-event/cell-gene-therapy-2025/continuing-education-credits) This link will be located in the CMS in the webinar CE tab – please enable third party PACE link



Labroots on Social:
Facebook: facebook.com/LabRootsInc
Twitter: twitter.com/LabRoots
LinkedIn: linkedin.com/company/labroots
Instagram: instagram.com/labrootsinc
Pinterest: pinterest.com/labroots
SnapChat: labroots_inc
Keynote Presentation: Outsmarting the Escape Artist Resistance in CAR-T Cell Therapy for...From Sewage to Safety: Digital PCRs Role in Tracking Microbial Threats to Support Public HealthOptofluidic Force Induction (OF2i®) & Raman: a BRAVE new way of continuously analyzing particlesThe Importance of Routine Coagulation TestingAutomated One-stop Purification Solution for Plasmid, Antibody and Protein | by Kamil Sekulski, PhDMastering DNA polymerase selection: tailoring your enzyme for PCR successNavigating STI & AMR Trends Implications for Public Health, Diagnostics, and TreatmentBeyond conventional: Using advanced spectral solutions to expand single cell and population analysisDr. Shella Keilholz: From Physics to Brain Imaging and the Search for Scientific TruthGenScript Introduction & Opening RemarksInnovating Lung Cancer Immunotherapy: Dr. Kellie Smith on T-Cells and Scientific LeadershipHealthy Aging in human cohorts: Proteomic Signatures for various human organ tissues and correspondg
Labroots |

Keynote Presentation: Outsmarting the Escape Artist Resistance in CAR-T Cell Therapy for...

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER